Showing 1 - 10 of 20 Gland and Hormone Related Diseases
A Double-Blind, Placebo-Controlled, Randomized Ph III Study of Ipatasertib in Combo With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, TNBC or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally adv ... Read more >

A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Georgia Michou

Phone: 713.441.1952

Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients. ... Read more >

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed ... Read more >

A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti ... Read more >

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Georgia Michou

Phone: 713.441.1952

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery ... Read more >

A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy ... Read more >

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Georgia Michou

Phone: 713.441.1952

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >

Ad5-SGE-REIC in prostate cancer

Status: Enrolling

Investigator: Brian Miles

Study Coordinator: Vivian MacDonnell

Phone: 714.441.8113

This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >

BAY94-8862-16244 (Finerenone) - FIDELIO

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

BAY94-8862-17530 (Finerenone) - FIGARO

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Clinical Phase Ib/II Trial of L-NMMA Plus Docetaxel in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Status: Enrolling

Investigator: Polly Niravath

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or metastatic triple neg ... Read more >

KOWA K-877-302

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

In patients with diabetes and high triglycerides, subjects will be given pemafibrate to help reduce triglycerides level and cardiovascular outcomes. ... Read more >

NN1218-4113

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and safety of fast-acting insulin aspart to NovoRap ... Read more >

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >

Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy.

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Georgia Michou

Phone: 713.441.1952

This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple neg ... Read more >

Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting el ... Read more >

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

Status: Active

Investigator: Constance Mobley

Study Coordinator: Susan Dorman

Phone: 713.441.6316

The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91. The secondary o ... Read more >